<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03652194</url>
  </required_header>
  <id_info>
    <org_study_id>Basmaciyan AOI 2017</org_study_id>
    <nct_id>NCT03652194</nct_id>
  </id_info>
  <brief_title>Study of Innate Host Immune Response to C. Glabrata Clinical Isolates Resistant to Echinocandins: Impact on the Management of Candidemia in High-risk Patients</brief_title>
  <acronym>CAHOHR</acronym>
  <official_title>Study of Innate Host Immune Response to C. Glabrata Clinical Isolates Resistant to Echinocandins: Impact on the Management of Candidemia in High-risk Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the context of Candida yeast infections, a large number of studies have been published&#xD;
      over the past two decades specifying the molecular mechanisms of antifungal resistance in&#xD;
      different Candida species. However, few of these studies have explored how these mechanisms&#xD;
      influence host immune response to this opportunistic pathogen. Recent advances in&#xD;
      understanding how the host's immune system responds to Candida have initiated the emergence&#xD;
      of a new research theme aimed at better understanding Candida's intrinsic and adaptive&#xD;
      resistance mechanisms to antifungals can modulate &quot;escape to&quot; or &quot;recognition by&quot; the host's&#xD;
      immune system. This knowledge could lead to (i) a better understanding of the predominance of&#xD;
      certain Candida species with antifungal resistance in certain patient populations, (ii) a&#xD;
      better understanding of why high levels of in vitro resistance are not necessarily correlated&#xD;
      with in vivo therapeutic failure, and (iii) effective immunotherapeutic strategies to control&#xD;
      Candida resistance to antifungals.&#xD;
&#xD;
      It is therefore crucial to investigate the impact of Candida's resistance to antifungals on&#xD;
      the host's innate immune response. Indeed, most antifungal resistance mechanisms have a&#xD;
      direct or indirect structural modification of the fungal wall. However, it is the composition&#xD;
      of this wall that is involved in the recognition of Candida by the host cell via the pattern&#xD;
      recognition receptors (PRRs). We therefore put forward the very probable hypothesis that&#xD;
      changes in the fungal wall, induced by the appearance of resistance, could alter the&#xD;
      recognition of Candida by PRRs and thus trigger a different immune response, either&#xD;
      qualitatively (type of cytokines secreted) or quantitatively (amplitude and duration of the&#xD;
      immune response). However, even if initial experimental data support the hypothesis of a&#xD;
      possible link between resistance and a modulation of the innate immune response in digestive&#xD;
      mucosa (the most frequent starting point for disseminated candidiasis), many questions remain&#xD;
      regarding (i) the proteins and mechanisms of the modulated immune cascade, (ii) the&#xD;
      modification of the immune response according to the Candida species in question and (iii)&#xD;
      the modification of the immune response according to the resistance phenotype in question.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of accession and invasion</measure>
    <time_frame>Baseline</time_frame>
    <description>In vitro study of different virulence markers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Test SytoxOrange</measure>
    <time_frame>Baseline</time_frame>
    <description>In vitro study of different cytotoxicity markers in digestive epithelial cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of the gene expression of the various cytokines associated with the immune response in digestive epithelial cells.</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">21</enrollment>
  <condition>Candidemia of C. Glabrata</condition>
  <arm_group>
    <arm_group_label>Reference strain ATCC</arm_group_label>
    <description>1 strain sensitive to all antifungals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinical isolates sensitive to all antifungal agents</arm_group_label>
    <description>10 clinical isolates sensitive to all</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Echinocandin-resistant clinical isolates</arm_group_label>
    <description>10 echinocandin-resistant clinical isolates (Eucast, Caspofungin &gt; 8µg/ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>in vitro evaluation of epithelial immune response during C. glabrata infection</intervention_name>
    <description>study of the expression of genes coding for different proteins involved in the RTqPCR activation cascade&#xD;
study of protein expression by the Western-Blot method</description>
    <arm_group_label>Clinical isolates sensitive to all antifungal agents</arm_group_label>
    <arm_group_label>Echinocandin-resistant clinical isolates</arm_group_label>
    <arm_group_label>Reference strain ATCC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates</intervention_name>
    <description>in vitro evaluation by measuring cell invasion, cell adhesion and by determining epithelial cell cytotoxicity.&#xD;
in vivo evaluation measured by a survival study on a CD-1 mouse model.</description>
    <arm_group_label>Clinical isolates sensitive to all antifungal agents</arm_group_label>
    <arm_group_label>Echinocandin-resistant clinical isolates</arm_group_label>
    <arm_group_label>Reference strain ATCC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Collection from the &quot;multicentric study of Echinocandin-resistance in Candida glabrata&#xD;
        candidemia&quot; (multicentre retrospective study on a cohort of 172 patients managed for a C.&#xD;
        glabrata cadidemia between 2013 and 2015).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  10 clinical isolates sensitive to all antifungal agents&#xD;
&#xD;
          -  10 echinocandin-resistant clinical isolates (Eucast, caspofungin &gt; 8µg/ml)&#xD;
&#xD;
        Clinical strains of C. glabrata susceptible or resistant to echinocandins will be selected&#xD;
        on selected criteria:&#xD;
&#xD;
          -  patient's immune status&#xD;
&#xD;
          -  therapeutic management&#xD;
&#xD;
          -  clinical developments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not applicable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chu Dijon Bourogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>August 28, 2018</last_update_submitted>
  <last_update_submitted_qc>August 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

